INMB
Inmune Bio, Inc.
Next earnings Aug 5, 2026 · consensus $-0.20 EPS
$1.42
▼ -4.70%$1.42▼ -77.17%
over 1Y
L $1.12EODHDH $7.37
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-4.7%
1W-0.7%
1M+1.4%
3M+26.8%
YTD-7.8%
1Y-77.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Revenue grew 257.1% YoY; but unprofitable (net margin -91866.0%).
Revenue (FY2025) $50.0K · FY2025
Inmune Bio, Inc. shows $50.0K in FY2025 revenue (+257.1% YoY), a -91866.0% net margin, and -195.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $181K | $374K | $155K | $14.0K | $50.0K |
| Gross profit | — | — | — | — | — |
| Operating income | -$29.2M | -$26.0M | -$29.7M | -$42.6M | -$47.4M |
| Net income | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| Diluted EPS | -$1.88 | -$1.52 | -$1.67 | -$2.11 | -$1.86 |
| Net margin | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$37.9M
EV / EBITDA—
EV / Sales758.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-121.7%
FCF yield-62.6%
Quality & risk
ROIC (est.)-77.3%
Free cash flow-$23.6M
Total debt$24.9M
Net cash-$170K
Altman Z-Score-10.52 distress
Piotroski F-Score3/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+15.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-232026-06-23open ↗8-KPeriod ending 2026-06-162026-06-17open ↗8-KPeriod ending 2026-06-022026-06-02open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-04-292026-05-05open ↗DEF 14APeriod ending 2026-06-162026-04-23open ↗10-KPeriod ending 2025-12-312026-03-30open ↗8-KPeriod ending 2026-02-272026-02-27open ↗8-KPeriod ending 2026-02-232026-02-23open ↗8-KPeriod ending 2026-02-192026-02-19open ↗8-KPeriod ending 2026-02-102026-02-13open ↗
Frequently asked
- Is Inmune Bio, Inc. (INMB) a buy?
- INMB currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 257.1% YoY; but unprofitable (net margin -91866.0%).
- What is Inmune Bio, Inc.'s quality score?
- INMB scores 41.50980392156862/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001711754, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 5:49:50 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.